Successful Treatment of Zanubrutinib in Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID) of B-Cell Clones (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0762; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Obinutuzumab was added; 6 months of combination therapy reduced SCr to 171 μmol/L and 24hUP to 0.93g. Discussion ZANU achieves good renal efficacy in PGNMID of B-cell lymphoproliferative clones; anti-CD20 antibody combination benefits refractory cases. Baseline characteristics of the three patients Abbreviations: HBV, hepatitis B virus; CLL, chronic lymphocytic leukemia; WM, Waldenström macroglobulinemia."
Chronic Lymphocytic Leukemia • Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Infectious Disease • Leukemia • Lupus Nephritis • Lymphoma • Lymphoplasmacytic Lymphoma • Nephrology • Renal Disease • Waldenstrom Macroglobulinemia
|
|
Fei Teng; Ke Zheng; Yubing Wen; Yan Zhang; Xuemei Li
|